New hope for stomach cancer patients who failed immunotherapy: drug combo trial launches
Disease control
Recruiting now
This study tests a combination of three drugs (SHR-1701, rivoceranib, and possibly SHR-2554) in 40 adults with advanced stomach or gastroesophageal junction cancer that has worsened after or was not tolerated during first-line immunotherapy. The goal is to see if the combination …
Phase: PHASE2 • Sponsor: Jingdong Zhang • Aim: Disease control
Last updated May 05, 2026 11:53 UTC